

Francisco Escamilla-Sevilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8209900/publications.pdf>

Version: 2024-02-01

32
papers

2,455
citations

471509

17
h-index

377865

34
g-index

39
all docs

39
docs citations

39
times ranked

4009
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,414
2	Do α -synuclein aggregates in autonomic plexuses predate Lewy body disorders?. <i>Neurology</i> , 2007, 68, 2012-2018.	1.1	184
3	Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. <i>Movement Disorders</i> , 2012, 27, 211-218.	3.9	105
4	Autotransplantation of Human Carotid Body Cell Aggregates for Treatment of Parkinson's Disease. <i>Neurosurgery</i> , 2003, 53, 321-330.	1.1	99
5	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 825-831.	1.9	88
6	Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 65-69.	1.9	67
7	Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 34-39.	1.9	55
8	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	3.9	47
9	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. <i>Nature Communications</i> , 2021, 12, 7342.	12.8	44
10	Cognitive Effects of Subthalamic Nucleus Stimulation in Parkinson's Disease: A Controlled Study. <i>European Neurology</i> , 2012, 68, 361-366.	1.4	38
11	Multidimensional Circadian Monitoring by Wearable Biosensors in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 157.	2.4	37
12	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. <i>Neurobiology of Aging</i> , 2016, 45, 213.e3-213.e9.	3.1	35
13	Validation of a Device for the Ambulatory Monitoring of Sleep Patterns: A Pilot Study on Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 356.	2.4	31
14	Unilateral pallidal stimulation for segmental cervical and truncal dystonia: Which side?. <i>Movement Disorders</i> , 2002, 17, 1383-1385.	3.9	28
15	Change of the melanocortin system caused by bilateral subthalamic nucleus stimulation in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 275-281.	2.1	23
16	Abnormal thermography in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 852-857.	2.2	23
17	Analysis of the genetic variability in Parkinson's disease from Southern Spain. <i>Neurobiology of Aging</i> , 2016, 37, 210.e1-210.e5.	3.1	23
18	Lack of validation of variants associated with cervical dystonia risk: A GWAS replication study. <i>Movement Disorders</i> , 2014, 29, 1825-1828.	3.9	15

#	ARTICLE	IF	CITATIONS
19	LRP10 in α -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032.	10.2	15
20	Association of Parkinson's disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records. <i>BMJ Open</i> , 2019, 9, e025574.	1.9	13
21	Structural genomic variations and Parkinson's disease. <i>Minerva Medica</i> , 2017, 108, 438-447.	0.9	11
22	BDNF Val66Met polymorphism in primary adult-onset dystonia: A case-control study and meta-analysis. <i>Movement Disorders</i> , 2014, 29, 1083-1086.	3.9	10
23	Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 108.	5.3	8
24	Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study. <i>Brain Sciences</i> , 2022, 12, 383.	2.3	7
25	Deep-Brain Stimulation for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2010, 363, 987-988.	27.0	6
26	Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. <i>Brain Sciences</i> , 2021, 11, 1027.	2.3	6
27	Pallidal vs Subthalamic Deep Brain Stimulation for Parkinson Disease: Winner and Loser or a Sharing of Honors?. <i>Archives of Neurology</i> , 2005, 62, 1642-3; author reply 1643.	4.5	5
28	Mutational spectrum of GNAL , THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review. <i>European Journal of Neurology</i> , 2021, 28, 1188-1197.	3.3	2
29	Neuropsychological Deficits Associated with Destruction of the Right Nigrostriatal Pathway. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 729-734.	1.8	1
30	Inflammatory bowel disease and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 57, 78-79.	2.2	1
31	Posthemorrhagic Hemiparkinsonism Treated by Unilateral Pallidal Stimulation. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 139-141.	1.5	0
32	La dificultad del diagnóstico de mareos y sÃncopes. <i>Revista Clinica Espanola</i> , 2015, 215, 291-292.	0.6	0